Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022

Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023

Published:2024-01-11 Issue:1 Volume:73 Page:16-23
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Payne Amanda B.,Novosad Shannon,Wiegand Ryan E.,Najdowski Morgan,Gomes Danica J.,Wallace Megan,Kelman Jeffrey A.,Sung Heng-Ming,Zhang Yue,Lufkin Bradley,Chillarige Yoganand,Link-Gelles Ruth

Publisher

Centers for Disease Control MMWR Office

Reference9 articles.

1. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales.;Knight;Circulation,2022

2. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.;Burn;Lancet Infect Dis,2022

3. Effectiveness of monovalent mRNA COVID-19 vaccination in preventing COVID-19–associated invasive mechanical ventilation and death among immunocompetent adults during the Omicron variant period—IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023.;DeCuir;MMWR Morb Mortal Wkly Rep,2023

4. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION Network, September 2022–April 2023.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2023

5. Long COVID after breakthrough SARS-CoV-2 infection.;Al-Aly;Nat Med,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines;Expert Review of Vaccines;2024-09-13

2. COVID-19 vaccination prevents venous thrombosis in patients with SARS-CoV-2 infection and thereafter;Blood Coagulation & Fibrinolysis;2024-07

3. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies;The Lancet Infectious Diseases;2024-05

4. Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024;MMWR. Morbidity and Mortality Weekly Report;2024-04-25